Press Release Details

Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO

September 28, 2015

Novel 10 kHz rapifleX Offers Breakthrough TOF/TOF Performance and Robustness for Primary Structure and PTM Determination in Proteomics, MALDI Tissuetyping and Biopharma Applications

VANCOUVER, British Columbia--(BUSINESS WIRE)-- At the 14th Human Proteome Organization World Congress (HUPO), Bruker today announced the new rapifleX MALDI-TOF/TOF mass spectrometer. MALDI-TOF/TOF is established as a powerful tandem mass spectrometry method for in-depth protein analysis. With its redesigned, next-generation TOF/TOF ion optics, the rapifleX system now offers significantly higher speed, mass resolution and mass accuracy. The rapifleX integrates a novel, 10 kHz smartbeam™ 3D scanning laser design for breakthrough mass-spec imaging capabilities with dramatically improved spatial resolution, image contrast and quality, and a new ion source for superior robustness and throughput in pathology research.

This Smart News Release features multimedia. View the full release here:

New rapifleX™ MALDI-TOF/TOF (Photo: Business Wire)


???pagination.previous??? ???

Tissue- and cell-type specific proteomics is a major advance for relevant biomarker discovery and identification, and requires MALDI tissue imaging studies which include the identification of detected biomarker candidates for validation and the subsequent development of targeted assays. The rapifleX MALDI-TOF/TOF extends the MALDI Tissuetyper® imaging capabilities with rapid, spatially resolved MS/MS data. It supports the patented ImageID™ workflow for biomarker discovery in MALDI imaging cohort studies by obtaining matching identifications of tryptic peptides in bottom-up imaging studies.

Dr. Dietrich Hauffe, Executive Vice President for Life Science Mass Spectrometry at Bruker Daltonics, commented: “With the rapifleX MALDI-TOF/TOF introduction, we can now offer both, greatly enhanced TOF/TOF performance for structural characterization, and breakthrough MS imaging capabilities for cutting-edge proteomics research laboratories, for biopharma customers, and for clinical researchers in pathology. Its unparalleled speed, throughput, structural capabilities, imaging capabilities, as well as MALDI ease of use and robustness, make the new rapifleX MALDI-TOF/TOF a game-changing new research and validation tool.”

About the rapifleX MALDI-TOF/TOF system

In addition to next-generation tissue imaging performance, the rapifleX MALDI-TOF/TOF system is well suited for detailed protein characterization in life science research and biopharmaceutical laboratories. The rapifleX MALDI-TOF/TOF system will improve many protein characterization tasks:

  • Peptide mass fingerprints for protein identification
  • Fast identification of post-translational modifications (PTM)
  • Fast identification of impurities
  • Top-down protein sequencing
  • T3-Sequencing to identify or confirm suspected modifications or sequence alterations at protein N- or C-termini. T3-Sequencing is patented for protein terminal structure determination.
  • Fully automated Disulfide Bond analysis of intact proteins without a priori assumptions using DisulfideDetect™ method and software.

The rapifleX™ MALDI-TOF/TOF system is for research use only.

About Bruker Corporation (NASDAQ: BRKR)

For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, Nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit

Source: Bruker Corporation

Investor Contact:

Bruker Corporation

Joshua Young, 1 978-667-9580, ext. 1479

Vice President, Investor Relations


Media Contact:

Bruker Daltonics

Bob Galvin, 44 7881 811287

Vice President, Business Unit Omics & Biopharma